Publication:
Treatment of Chronic Hepatitis C in Special Populations

Simple item page
dc.contributor.authorChalermrat Bunchorntavakulen_US
dc.contributor.authorTawesak Tanwandeeen_US
dc.contributor.otherRangsit Universityen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-11-23T10:29:26Z
dc.date.available2018-11-23T10:29:26Z
dc.date.issued2015-12-01en_US
dc.description.abstract© 2015 Elsevier Inc. The management of hepatitis C virus (HCV) infection in special populations is challenging. The efficacy and safety data of the currently approved all-oral direct-acting antiviral combinations, including sofosbuvir, ledipasvir, daclatasvir, paritaprevir/ritonavir/ombitasvir plus dasabuvir (3D), and ribavirin, is compelling for use in special HCV populations, as has recently been recommended by expert guidelines. The treatment regimens and sustained virological response rates for special populations are nearly similar to those of the general HCV population. Sofosbuvir is not recommended in patients with severe renal impairment, and simeprevir and 3D regimen are not recommended for those with decompensated liver disease.en_US
dc.identifier.citationGastroenterology Clinics of North America. Vol.44, No.4 (2015), 883-900en_US
dc.identifier.doi10.1016/j.gtc.2015.06.002en_US
dc.identifier.issn15581942en_US
dc.identifier.issn08898553en_US
dc.identifier.other2-s2.0-84947616929en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/36234
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84947616929&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleTreatment of Chronic Hepatitis C in Special Populationsen_US
dc.typeReviewen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84947616929&origin=inwarden_US

Files

Collections

Scopus 2011-2015